RAS Dialogue Blog
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
A Conversation with Arul ChinnaiyanArul Chinnaiyan and colleagues discovered a strong interaction between the KRAS and AGO2 proteins that seems to inhibit KRAS signaling. They are also pioneers in using genomic data to guide therapy for cancer patients.
-
Nutritional Requirements of Pancreatic Cancers - A Conversation with Dafna Bar-SagiSolid tumors in humans develop primarily from epithelial cells, which have different functions in different tissues. Pancreatic cancers derive much of their nutrition from proteins consumed from their environment.
-
A Conversation with Elizabeth JaffeeImmunotherapy uses the patient's own immune system to fight cancer, but some tumors lack significant numbers of immune cells. Elizabeth Jaffee has invented new therapies that are designed to attract immune cells to penetrate tumors.
-
Faint Light at the End of the TunnelMany cancers are dependent on an overactive MAPK pathway. While progress in inhibiting mutant RAS proteins is still in its early phase, third-generation drugs that inhibit the next protein in the pathway, RAF, are being tested. Gideon Bollag of Plexxikon describes some of the challenges of developing inhibitors of RAF.
-
Mutation-Specific Approaches to KRAS Cancers: What We Can Learn from G12C-Directed InhibitorsDr. Sharon Campbell discusses recent advances in targeting specific mutant forms of KRAS proteins in cancers.